China SXT Pharmaceuticals, Inc (SXTC) Fair Value & Analysis
Healthcare · US · Market cap $10.7M
China SXT Pharmaceuticals, Inc
SXTC · US
Fair value as of: Jul 19, 2026
From 1 valuation models · updated today
Fair value updated Jul 19, 2026, revised from $19.05 to $3.38 (−82.3%) since Jun 24, 2026. Share price +10.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $1.30 – $300.00 · fair‑value band $2.23 – $4.23 · the $2.45 price screens below the $3.38 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
China SXT Pharmaceuticals, Inc (SXTC) currently trades at $2.45, while our model-based Fair Value estimate is $3.38, implying the stock looks roughly 38.0% undervalued today. We read business quality at 25/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at $1.5M. Revenue declined 24.5% year over year. It earns a return on equity of -50.3%. The balance sheet holds a net cash position of $17.1M. Fundamentals as of Jul 19, 2026
Our scenario range runs from $2.23 (bear case) to $4.23 (bull case); at $2.45, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 38%, SXTC screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
China SXT Pharmaceuticals, Inc reported revenue of $1.7M in FY2025 versus $4.8M in FY2021, a compound −22.3%/yr. Reported net income was −$3.3M in FY2025.
Is SXTC fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.60 | HK$15.73 | -47% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Lupin Limited LUPIN | ₹2,247 | ₹2,697 | +20% |
| Mankind Pharma Limited MANKIND | ₹2,376 | ₹1,085 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is China SXT Pharmaceuticals, Inc (SXTC) undervalued?
What is the fair value of SXTC?
What is the quality score of SXTC?
What is the revenue of China SXT Pharmaceuticals, Inc (SXTC)?
What is the net profit margin of SXTC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when China SXT Pharmaceuticals, Inc reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of China SXT Pharmaceuticals, Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.